Products

Angiochem has moved beyond physiological and scientific barriers to discover and develop a new class of pharmaceuticals. These breakthrough products are designed to cross the blood-brain barrier to treat brain cancer, Parkinson’s disease, type 2 diabetes/obesity, pain, and other unmet medical needs.

With a number of products currently in clinical and preclinical studies, Angiochem is developing therapeutic solutions designed to achieve clinically meaningful outcomes.

Oncology

Treating primary brain cancers and cancers that have metastasized to the brain has proven challenging. However, in early-stage clinical trials, GRN1005 has demonstrated anti-cancer activity. More >

Pain

Current therapies for managing moderate to severe pain from cancer, post-operative surgery, and neuropathic pain have significant limitations. But ANG2002 has the potential to be a first in class analgesic drug, without the side effects of opiates. More >

Type 2 Diabetes and Obesity

The connection between the hormone leptin and obesity is well-established. Angiochem has discovered that bypassing the impaired leptin-receptor with ANG2004 is leading to weight loss in animal studies, with the potential to impact type 2 diabetes. More >

Parkinson's Disease

Parkinson's disease is the second largest neurological illness in the elderly, after Alzheimer’s. Current treatments do not address the underlying disease progression, but ANG2008 is showing promise in preclinical studies. More >